Urges NJ DOH to increase public awareness on effects of xylazine.
Impact
The resolution highlights the serious health risks posed by xylazine, which is not approved for human use, and functions as a central nervous system depressant. Users may experience drowsiness, amnesia, and dangerously low vital signs. The NJ DOH is urged to initiate educational campaigns to inform the community about these risks and provide resources for understanding the dangers of using xylazine. Potentially, this could lead to enhanced public awareness efforts in combating substance abuse and preventing overdoses linked to this drug combination.
Summary
Senate Resolution No. 118 (SR118) addresses a rising public health concern regarding the drug xylazine, also known by its street names 'Tranq' and 'Zombie Drug'. This resolution urges the New Jersey Department of Health (NJ DOH) to take proactive measures in educating the public about the dangers associated with xylazine. This non-opioid veterinary tranquilizer has recently emerged as a significant factor in overdose deaths in New Jersey and nearby states, as it is increasingly being used recreationally in conjunction with other drugs, such as fentanyl.
Contention
Notably, xylazine's presence in the drug supply raises significant concerns, particularly because it complicates overdose treatment; naloxone, a standard treatment for opioid overdoses, is ineffective against xylazine-related incidents. The full extent of the overdose crisis exacerbated by xylazine remains largely undocumented, but data indicate its spread throughout the United States, with the Northeast facing the highest number of associated deaths. This resolution aims to mitigate the public health threat posed by xylazine and respond to the growing challenges faced by communities dealing with substance misuse.
Final_notes
In conclusion, SR118 serves as a crucial step in addressing an urgent health crisis in New Jersey by promoting awareness and education around the dangers of xylazine. As it calls on the NJ DOH to enhance its public health communication regarding this substance, the resolution reflects broader efforts to safeguard communities and reduce the incidence of overdose deaths.
Supporting the mission and goals of National Fentanyl Awareness Day in 2025, including increasing individual and public awareness of the impact of fake or counterfeit fentanyl pills on families and young people.
A resolution supporting the mission and goals of National Fentanyl Awareness Day in 2025, including increasing individual and public awareness of the impact of fake or counterfeit fentanyl pills on families and young people.